BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

The U.S. is trying to fight a 21st century pandemic with prehistoric clinical trials -- and achieving the kind of efficiency you might expect. In the last six months, tens of thousand of patients have...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy  Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 27, 2020
Product Development

argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

Armed with pivotal data showing efficacy for its myasthenia gravis candidate, argenx plans to submit a BLA by year-end for efgartigimod. If approved, it would provide patients with an alternative mechanism to that of Alexion’s...
BioCentury | May 20, 2020
Finance

$145M raise positions Rallybio to bring first rare disease program into clinic

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

Fortress Biotech broke from its mold of licensing clinical assets to access a Columbia University peptide nucleic acid technology in discovery. The new technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

With its purchase of hematology company Portola at a triple-digit premium, Alexion is signaling that it believes its commercial expertise can boost sales of Factor Xa reversal agent Andexxa/Ondexxya to meet expectations where Portola had...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
Items per page:
1 - 10 of 1077
BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

The U.S. is trying to fight a 21st century pandemic with prehistoric clinical trials -- and achieving the kind of efficiency you might expect. In the last six months, tens of thousand of patients have...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy  Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 27, 2020
Product Development

argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

Armed with pivotal data showing efficacy for its myasthenia gravis candidate, argenx plans to submit a BLA by year-end for efgartigimod. If approved, it would provide patients with an alternative mechanism to that of Alexion’s...
BioCentury | May 20, 2020
Finance

$145M raise positions Rallybio to bring first rare disease program into clinic

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

Fortress Biotech broke from its mold of licensing clinical assets to access a Columbia University peptide nucleic acid technology in discovery. The new technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

With its purchase of hematology company Portola at a triple-digit premium, Alexion is signaling that it believes its commercial expertise can boost sales of Factor Xa reversal agent Andexxa/Ondexxya to meet expectations where Portola had...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
Items per page:
1 - 10 of 1077